[go: up one dir, main page]

PT2895188T - Etanercept dobrado corretamente de pureza elevada e rendimento excelente - Google Patents

Etanercept dobrado corretamente de pureza elevada e rendimento excelente

Info

Publication number
PT2895188T
PT2895188T PT138380167T PT13838016T PT2895188T PT 2895188 T PT2895188 T PT 2895188T PT 138380167 T PT138380167 T PT 138380167T PT 13838016 T PT13838016 T PT 13838016T PT 2895188 T PT2895188 T PT 2895188T
Authority
PT
Portugal
Prior art keywords
high purity
correctly folded
excellent yield
folded etanercept
etanercept
Prior art date
Application number
PT138380167T
Other languages
English (en)
Inventor
Arakawa Tsutomu
Farrar Douglas
Original Assignee
Coherus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50233493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2895188(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Coherus Biosciences Inc filed Critical Coherus Biosciences Inc
Publication of PT2895188T publication Critical patent/PT2895188T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PT138380167T 2012-09-11 2013-09-10 Etanercept dobrado corretamente de pureza elevada e rendimento excelente PT2895188T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261699552P 2012-09-11 2012-09-11

Publications (1)

Publication Number Publication Date
PT2895188T true PT2895188T (pt) 2018-02-08

Family

ID=50233493

Family Applications (1)

Application Number Title Priority Date Filing Date
PT138380167T PT2895188T (pt) 2012-09-11 2013-09-10 Etanercept dobrado corretamente de pureza elevada e rendimento excelente

Country Status (33)

Country Link
US (6) US20140072560A1 (pt)
EP (1) EP2895188B1 (pt)
JP (3) JP2015533797A (pt)
KR (2) KR102250937B1 (pt)
CN (2) CN110051823A (pt)
AR (1) AR092532A1 (pt)
AU (2) AU2013315750B9 (pt)
BR (1) BR112015005161A2 (pt)
CA (1) CA2882551A1 (pt)
CL (1) CL2015000572A1 (pt)
CO (1) CO7400876A2 (pt)
CY (1) CY1120062T1 (pt)
DK (1) DK2895188T3 (pt)
DO (1) DOP2015000055A (pt)
EA (1) EA031324B1 (pt)
EC (1) ECSP15014138A (pt)
ES (1) ES2657377T3 (pt)
HR (1) HRP20180182T1 (pt)
HU (1) HUE036524T2 (pt)
IL (2) IL237311B (pt)
IN (1) IN2015KN00452A (pt)
LT (1) LT2895188T (pt)
MX (2) MX360044B (pt)
NO (1) NO2972131T3 (pt)
PE (2) PE20150996A1 (pt)
PL (1) PL2895188T3 (pt)
PT (1) PT2895188T (pt)
RS (1) RS57013B1 (pt)
SG (1) SG11201501460RA (pt)
SI (1) SI2895188T1 (pt)
SM (1) SMT201800163T1 (pt)
TW (2) TWI609877B (pt)
WO (1) WO2014043103A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2776657T3 (es) 2005-06-14 2020-07-31 Amgen Inc Formulaciones de proteínas autotamponantes
HK1200721A1 (en) 2011-10-18 2015-08-14 科荣生生物科学公司 Etanercept formulations stabilized with xylitol
US10485869B2 (en) 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
CN110051823A (zh) * 2012-09-11 2019-07-26 科荣生生物科学公司 高纯度和优异产量的正确折叠的依那西普
RU2698654C2 (ru) * 2014-06-13 2019-08-28 Люпин Лимитед Способ очистки белка слияния
ES2733298T3 (es) * 2014-07-18 2019-11-28 Sandoz Ag Cuantificación de TNFR2:Fc plegado erróneamente
MX394035B (es) 2014-12-31 2025-03-21 Lg Chemical Ltd Procedimiento para preparar una proteina de fusion tnfr-fc que contiene un contenido objetivo de impurezas.
EP3268042B1 (en) 2015-03-13 2024-11-27 Samsung Bioepis Co., Ltd. Anti-tnf-alpha polypeptide composition and use thereof
SG11201804083QA (en) * 2015-11-18 2018-06-28 Merck Patent Gmbh Opposite ph-salt gradients for improved protein separations
JP2018538268A (ja) * 2015-11-18 2018-12-27 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ イオン交換クロマトグラフィーにおける改善されたタンパク質分離
BR112018075516A2 (pt) * 2016-06-17 2019-10-01 Genentech, Inc. purificação de anticorpos multiespecíficos
WO2018075818A1 (en) * 2016-10-21 2018-04-26 Amgen Inc. Pharmaceutical formulations and methods of making the same
EP4467565A3 (en) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf alpha antibody formulations
EP3601332A1 (en) * 2017-03-24 2020-02-05 Council of Scientific and Industrial Research A process for the purification of recombinant antibody fragments
CA3042126A1 (en) 2018-05-03 2019-11-03 Michael A. Portman Methods of treating kawasaki disease
CN112876567A (zh) * 2019-11-29 2021-06-01 广东菲鹏制药股份有限公司 Fc融合蛋白及其纯化方法
CA3182368A1 (en) 2020-05-01 2021-11-04 Kashiv Biosciences, Llc An improved process of purification of protein
US20240156907A1 (en) * 2021-03-16 2024-05-16 Kashiv Biosciences, Llc Novel formulation of fusion protein
WO2022234412A1 (en) * 2021-05-03 2022-11-10 Lupin Limited A process for purification of fc-fusion proteins
CN118414350A (zh) * 2021-10-19 2024-07-30 阿特根公司 纯化具有igg fc结构域的融合蛋白的方法

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
EP0417563B1 (de) 1989-09-12 2000-07-05 F. Hoffmann-La Roche Ag TNF-bindende Proteine
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
DE59109032D1 (de) 1990-06-28 1998-09-03 Hoechst Ag Fusionsproteine mit immunglobulinanteilen, ihre Herstellung und Verwendung
EP0620739A4 (en) 1992-09-15 1997-01-15 Immunex Corp Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists.
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
CA2366785C (en) 1999-04-19 2012-02-07 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
MXPA02007683A (es) 2000-02-10 2002-12-13 American Home Prod Metodo para tratar o inhibir la lesion celular o muerte celular.
WO2002013860A1 (en) 2000-08-11 2002-02-21 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing preparations
CZ20032208A3 (cs) 2001-02-23 2004-01-14 Immunex Corporation Zvýšený výtěžek aktivních proteinů
US20030180287A1 (en) 2002-02-27 2003-09-25 Immunex Corporation Polypeptide formulation
WO2004017955A1 (en) * 2002-08-22 2004-03-04 Vasopharm Biotech Gmbh L-arginine containing pharmaceutical composition
US20040115263A1 (en) 2002-08-26 2004-06-17 Robertson David W. Use of bupropion for treating restless legs syndrome
EP1603596B1 (en) 2003-02-28 2008-05-07 Ares Trading S.A. Liquid formulations of tumor necrosis factor-binding protein tbp-1
US20060177444A1 (en) 2003-03-20 2006-08-10 Tatsuo Horizoe Concomitant drug as therapeutic agent for inflammatory bowel disease
US7276477B2 (en) 2003-08-01 2007-10-02 Amgen Inc. Crystals of etanercept and methods of making thereof
RS20060259A (sr) 2003-10-14 2008-08-07 Intermune Inc., Makrociklične karboksilne kiseline i acilsulfonamidi kao inhibitori replikacije hcv
EP1718386A1 (en) * 2004-02-27 2006-11-08 GE Healthcare Bio-Sciences AB A process for the purification of antibodies
JP5554466B2 (ja) 2004-03-01 2014-07-23 味の素株式会社 抗ヒトＴＮＦ−α抗体活性低下抑制剤
ES2456015T3 (es) 2004-03-05 2014-04-21 Dsm Ip Assets B.V. Procedimiento para cultivar células mediante perfusión continua y flujo tangencial alternante
US20070196364A1 (en) 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
US7300773B2 (en) 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
AU2006244014B2 (en) 2005-05-10 2011-03-17 Biogen Ma Inc. Treating and evaluating inflammatory disorders
CA2610987C (en) 2005-06-10 2013-09-10 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
NZ569108A (en) 2005-12-20 2011-09-30 Bristol Myers Squibb Co Formulations of CTLA4Ig stabilised using sugars
JP5405122B2 (ja) 2005-12-21 2014-02-05 ワイス・エルエルシー 低粘度のタンパク質製剤およびその用途
JP2009525986A (ja) 2006-02-03 2009-07-16 メディミューン，エルエルシー タンパク質製剤
BRPI0709598A8 (pt) 2006-03-17 2019-01-08 Biogen Idec Inc composições de polipeptídeos estabilizados
JP2009534390A (ja) 2006-04-21 2009-09-24 アムジェン インコーポレイテッド 生物医薬品製剤のための緩衝剤
JP5631591B2 (ja) 2006-10-06 2014-11-26 アムジエン・インコーポレーテツド 安定な抗体製剤
MX2009003982A (es) 2006-10-20 2009-04-27 Amgen Inc Formulaciones de polipeptido estables.
EP2395077A1 (en) 2006-11-03 2011-12-14 Wyeth LLC Glycolysis-inhibiting substances in cell culture
EP2129401B8 (en) 2006-12-21 2020-01-15 Amgen Inc. Stable buffered formulations containing polypeptides
US7691980B2 (en) * 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
SI2115126T1 (sl) 2007-03-02 2015-06-30 Wyeth Llc Uporaba bakra in glutamata v celični kulturi za proizvodnjo polipeptidov
EP2014760A1 (en) 2007-06-13 2009-01-14 CMC Biopharmaceuticals A/S A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process
ES2707815T3 (es) 2007-06-14 2019-04-05 Biogen Ma Inc Formulaciones de anticuerpo natalizumab
KR20210049186A (ko) 2007-11-30 2021-05-04 애브비 바이오테크놀로지 리미티드 단백질 제형 및 이의 제조방법
US20110129468A1 (en) * 2008-02-29 2011-06-02 Biogen Idec Ma Inc. Purified immunoglobulin fusion proteins and methods of their purification
WO2009146755A1 (en) * 2008-06-05 2009-12-10 Affibody Ab Polypeptide
WO2011015926A1 (en) 2009-08-03 2011-02-10 Avesthagen Limited A process of fermentation, purification and production of recombinant soluble tumour necrosis factor alfa receptor (tnfr) - human igg fc fusion protein
SG177577A1 (en) 2009-08-07 2012-03-29 Emd Millipore Corp Methods for purifying a target protein from one or more impurities in a sample
MX355650B (es) 2009-08-11 2018-04-26 Genentech Inc Produccion de proteinas en medios de cultivo de celulas libres de glutamina.
US20120208986A1 (en) * 2009-10-20 2012-08-16 Wenger Marc D Use of mixed mode chromatography for the capture and purification of basic antibody products
EP2516467A2 (en) 2009-12-23 2012-10-31 Emergent Product Development Seattle, LLC Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
JP6347949B2 (ja) 2010-04-26 2018-06-27 ノバルティス アーゲー 改良型細胞培養培地
CN102946858B (zh) * 2010-05-10 2015-09-30 英塔斯制药有限公司 含有免疫球蛋白Fc的多肽的液体制剂
WO2012013980A1 (en) 2010-07-30 2012-02-02 Arecor Limited Stabilized aqueous antibody compositions
CA2807607A1 (en) 2010-08-20 2012-02-23 Wyeth Llc Cell culture of growth factor-free adapted cells
US20130224855A1 (en) 2010-08-31 2013-08-29 Abhishek Gupta Culture medium for eukaryotic cells
RU2610667C2 (ru) * 2010-10-11 2017-02-14 Эббви Бахамаз Лтд., Способ очистки белков
WO2012143418A1 (en) 2011-04-20 2012-10-26 Sandoz Ag STABLE PHARMACEUTICAL LIQUID FORMULATIONS OF THE FUSION PROTEIN TNFR:Fc
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
US11292829B2 (en) 2011-07-01 2022-04-05 Amgen Inc. Mammalian cell culture
DK2726090T3 (da) * 2011-07-01 2020-01-20 Biogen Ma Inc Argininfri tnfr: fc-fusionspolypeptidsammensætninger
CN103814044A (zh) * 2011-07-08 2014-05-21 默沙东公司 纯化fc-融合蛋白的方法
ES2651483T3 (es) * 2011-08-17 2018-01-26 Ares Trading S.A. Método para preparar la forma activa de la proteína de fusión TNRF-Fc
US10485869B2 (en) * 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
HK1200721A1 (en) * 2011-10-18 2015-08-14 科荣生生物科学公司 Etanercept formulations stabilized with xylitol
BR112015000229A2 (pt) * 2012-07-09 2017-06-27 Coherus Biosciences Inc formulações aquosas estáveis de etanercept
CN110051823A (zh) * 2012-09-11 2019-07-26 科荣生生物科学公司 高纯度和优异产量的正确折叠的依那西普
WO2016015163A1 (en) * 2014-07-31 2016-02-04 Mtt Innovation Incorporated Numerical approaches for free-form lensing: area parameterization free-form lensing
US20160108634A1 (en) * 2014-10-16 2016-04-21 Ronald Uphold Pool Cover Hanger Device

Also Published As

Publication number Publication date
EP2895188A4 (en) 2016-05-25
EA031324B1 (ru) 2018-12-28
AU2013315750A1 (en) 2015-03-05
IL267452B (en) 2021-05-31
PE20150996A1 (es) 2015-08-01
US20180037642A1 (en) 2018-02-08
SMT201800163T1 (it) 2018-05-02
BR112015005161A2 (pt) 2017-07-04
JP6913066B2 (ja) 2021-08-04
LT2895188T (lt) 2018-04-10
US10947306B2 (en) 2021-03-16
AU2013315750B2 (en) 2018-07-12
CO7400876A2 (es) 2015-09-30
IL267452A (en) 2019-08-29
KR20150056601A (ko) 2015-05-26
US10954293B2 (en) 2021-03-23
ECSP15014138A (es) 2016-01-29
HUE036524T2 (hu) 2018-07-30
US20190300600A1 (en) 2019-10-03
AU2018247244B2 (en) 2020-05-28
PE20200607A1 (es) 2020-03-10
KR20200085937A (ko) 2020-07-15
IL237311A0 (en) 2015-04-30
TW201425331A (zh) 2014-07-01
TWI716649B (zh) 2021-01-21
JP2015533797A (ja) 2015-11-26
IL237311B (en) 2019-07-31
EP2895188B1 (en) 2017-11-15
WO2014043103A1 (en) 2014-03-20
IN2015KN00452A (pt) 2015-07-17
MX2015003090A (es) 2015-07-14
ES2657377T3 (es) 2018-03-05
AU2013315750B9 (en) 2018-11-15
TW201803593A (zh) 2018-02-01
CN110051823A (zh) 2019-07-26
MX2018012749A (es) 2020-11-12
TWI609877B (zh) 2018-01-01
US10954294B2 (en) 2021-03-23
CN104902914A (zh) 2015-09-09
CA2882551A1 (en) 2014-03-20
JP2019038817A (ja) 2019-03-14
AU2018247244A1 (en) 2018-11-01
US11001627B2 (en) 2021-05-11
HRP20180182T1 (hr) 2018-04-20
SI2895188T1 (en) 2018-05-31
EA201590542A1 (ru) 2015-07-30
US10954295B2 (en) 2021-03-23
AR092532A1 (es) 2015-04-22
PL2895188T3 (pl) 2018-06-29
KR102133699B1 (ko) 2020-07-14
CL2015000572A1 (es) 2016-02-05
US20140072560A1 (en) 2014-03-13
US20190300601A1 (en) 2019-10-03
DK2895188T3 (en) 2018-02-26
JP2021100929A (ja) 2021-07-08
SG11201501460RA (en) 2015-04-29
CN104902914B (zh) 2019-01-01
CY1120062T1 (el) 2018-12-12
US20190300602A1 (en) 2019-10-03
MX360044B (es) 2018-10-19
KR102250937B1 (ko) 2021-05-12
NO2972131T3 (pt) 2018-04-21
EP2895188A1 (en) 2015-07-22
RS57013B1 (sr) 2018-05-31
DOP2015000055A (es) 2015-04-30
US20190330325A1 (en) 2019-10-31

Similar Documents

Publication Publication Date Title
IL267452B (en) Ethanercept is correctly folded with a high degree of cleanliness and excellent utilization
GB2499314B (en) Replacement-gate finfet structure and process
ZA201500231B (en) Photovoltaic frame fastener
GB201201506D0 (en) Photovoltaic panel circuitry
GB2509046B (en) Improvement in or relating to capsules
EP2855745A4 (en) METHODS RELATING TO ADALIMUM AB
EP2932375A4 (en) ADAPTATION OF OPPORTUNITY IN CONTEXT
EP2806761A4 (en) COMPONENTS OF A SEASACK
PL2806773T3 (pl) Moduł do zaparzania
PT2888284T (pt) Anticorpos dirigidos contra haptenos de risperidona e a sua utilização
IL235425B (en) History of lysine-glutamic acid di-peptide
IL239824A0 (en) Use of inos inhibitors to increase viral survival in culture
EP2888277A4 (en) ANTIBODIES AGAINST PALIPERIDONE AND USE THEREOF
ZA201503367B (en) Heteroaryl derivatives and uses thereof
GB2503225B (en) Balun
GB201210817D0 (en) Balun
EP2909309A4 (en) COMPOSITIONS AND METHODS FOR VITAMINOUS FERMENTATES
GB201200138D0 (en) Convertible coffee-dining table
PT2906528T (pt) Processo para a obtenção de anilina pura
AU343221S (en) Zipper securing aid
ZA201504198B (en) Methods for banana yield protection and enhancement
HUP1200259A2 (en) Shopping bag which can also be as litterbag
GB201201013D0 (en) Sleeping bag
IL212583A0 (en) Marketng by means of placing independent show cascs in shopping cenlers
GB201220447D0 (en) Releasable fastener